Sam Brusco, Associate Editor04.03.23
Enovis has entered an agreement to acquire Novastep, a subsidiary of Paris-based Amplitude Surgical, and maker of clinically proven foot and ankle solutions. The transaction is expected to close in Q2 2023.
Novastep has about $20 million in annual revenues and is a leading player in minimally invasive surgery (MIS) foot and ankle solutions. The company’s Pecaplasty MIS bunion system offers surgeons predictable, accurate, and controlled implant placement. MIS bunion procedures, according to the company, can significantly boost outcomes and bring about faster recovery with reduced scarring and pain.
Novastep’s portfolio of CE-marked forefoot and midfoot implants, as well as a strong outside U.S. channel, will strengthen Enovis’ position in the global foot and ankle market.
“Adding Novastep to our growing Foot & Ankle business is an important step in the execution of our strategic priorities and a great example of our focus on MedTech innovation that drives growth while improving patient outcomes,” Matt Trerotola, CEO of Enovis told the press. “We are excited to expand our portfolio of clinically differentiated foot and ankle solutions and accelerate our international strategy with Novastep’s market-leading innovation, and advanced technology.”
“We look forward to joining the Enovis team and developing the next generation of foot and ankle solutions that improve patient outcomes,” added Gregory Gledel, president and CEO of Novastep SAS. “Like Enovis, we are committed to working with healthcare professionals to drive the industry forward and together, I know we will make an even greater impact around the world.”
Novastep has about $20 million in annual revenues and is a leading player in minimally invasive surgery (MIS) foot and ankle solutions. The company’s Pecaplasty MIS bunion system offers surgeons predictable, accurate, and controlled implant placement. MIS bunion procedures, according to the company, can significantly boost outcomes and bring about faster recovery with reduced scarring and pain.
Novastep’s portfolio of CE-marked forefoot and midfoot implants, as well as a strong outside U.S. channel, will strengthen Enovis’ position in the global foot and ankle market.
“Adding Novastep to our growing Foot & Ankle business is an important step in the execution of our strategic priorities and a great example of our focus on MedTech innovation that drives growth while improving patient outcomes,” Matt Trerotola, CEO of Enovis told the press. “We are excited to expand our portfolio of clinically differentiated foot and ankle solutions and accelerate our international strategy with Novastep’s market-leading innovation, and advanced technology.”
“We look forward to joining the Enovis team and developing the next generation of foot and ankle solutions that improve patient outcomes,” added Gregory Gledel, president and CEO of Novastep SAS. “Like Enovis, we are committed to working with healthcare professionals to drive the industry forward and together, I know we will make an even greater impact around the world.”